Search

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.

… Tuesday, February 25, 2020 Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited

ATLANTA, June 4, 2006 - According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.

… Sunday, June 4, 2006 According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer , also known as metastatic renal cell carcinoma (mRCC). The study is being presented today

Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.

… Wednesday, March 14, 2012 Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial

Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center for Cancer Care. The 750,000-square-foot, 23-story outpatient cancer center on East 74th Street and FDR Drive is made possible by a landmark gift of $150 million from Mr. Koch, the largest single gift in the history of the institution.

… Thursday, May 11, 2017 Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center

Learn how advanced basal cell carcinoma can be treated with a new combination radiation and drug therapy.

… Thursday, April 18, 2024 Millions of Americans develop basal cell carcinoma basal cell carcinoma (BCC) on their skin, usually on their face, neck, or head. It’s the most common form of skin cancer skin cancer and is rarely fatal, but it can be uncomfortable and unsightly. BCC can usually be removed with

One of MSK’s leading immunologists turned 60 on Friday, and scientists came to celebrate.

… Monday, September 12, 2016 Alexander (Sasha) Rudensky with former students and colleagues Sasha Rudensky (center left) with former students and colleagues Greg Barton (left), Jason Fontenot (center right), and Nicholas Arpaia (right). Dr. Rudensky with Dr. Barton of the University of California, Berkeley

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with relapsed or refractory non-Hodgkin lymphomas, profound immune suppression, and predicting the likelihood of treatment failure.

… Tuesday, April 1, 2025 While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune suppression and predicting the likelihood of treatment failure remain significant

MSK nanotechnology researchers have developed an innovative approach for measuring the permeability of living tumors.

… Tuesday, February 23, 2016 Summary Tumor permeability can be a critical factor in how well a cancer therapy works. MSK researchers developed a method to measure this by creating living tumor spheroids and infiltrating them with very small carbon nanotubes that give off infrared light. The more light

Learn more about how MSK is helping a new generation of patients — including triathlete Derrick Edwin — to navigate work and careers while undergoing treatment for cancer.

… Thursday, April 10, 2025 One November morning in 2021, Derrick Edwin woke with pain in his side — as a triathlete in peak condition, he knew something was off. “Two months before, I had completed an Ironman — that’s a 2.4-mile swim, 112 miles on the bike, followed by a full marathon — and I felt great

Obtenga más información sobre cómo MSK está ayudando a una nueva generación de pacientes, entre ellos el triatleta Derrick Edwin, a gestionar el trabajo y la carrera profesional y el tratamiento contra el cáncer.

… Thursday, April 10, 2025 Una mañana de noviembre de 2021, Derrick Edwin se despertó con dolor en un costado. Como triatleta en óptimas condiciones, sabía que algo andaba mal. “Dos meses antes, había completado un Ironman, eso implica 2.4 millas de natación, 112 millas en bicicleta, seguidas de un maratón